Die ProDerm (Progress in Dermatomyositis)-Studie
Die ProDerm (Progress in Dermatomyositis)-Studie Erste Phase-III-Studie zum Einsatz intravenöser Immunglobuline bei der Dermatomyositis The progress in dermatomyositis (ProDerm) study First …
Die ProDerm(Progress in Dermatomyositis)-Studie
Nachdem in 2 früheren placebokontrollierten Studien mit 15 bzw. 26 Patienten kontroverse Daten zum Ansprechen auf IVIG bezüglich der Myositisaktivität bestanden [ 3 , 4 ], liefert die ProDerm-Studie als …
Die ProDerm (Progress in Dermatomyositis)-StudieThe progress in ...
Download Citation | On Jun 2, 2023, Jutta Bauhammer published Die ProDerm(Progress in Dermatomyositis)-StudieThe progress in dermatomyositis (ProDerm) study: Erste Phase-III-Studie …
Die ProDerm(Progress in Dermatomyositis)-Studie
Die ProDerm(Progress in Dermatomyositis)-Studie Erste Phase-III-Studie zum Einsatz intravenöser Immunglobuline bei der Dermatomyositis Redaktion Christoph Fiehn, Baden-Baden Bernhard …
Die ProDerm (Progress in Dermatomyositis)-Studie
Hintergrund. Intravenöse Immunglobuline (IVIG)werdenalsZweit-oderDrittlinientherapie „off-label“ bei schwerer Dermatomyositis (DM) eingesetzt. Der Einsatz wird nach Therapieversagen von …
Publikation zur ProDerm-Studie zur Behandlung der Dermatomyositis …
Eine neue Publikation von Dr. Jutta Bauhammer welche die Ergebnisse der ProDerm-Studie zur Behandlung der Dermatomyositis mit intravenösen Immmunglobulinen zusammenfasst. Erstmals …
Prospective, double-blind, randomized, placebo-controlled phase III ...
The objective of the ProDERM (Progress in DERMatomyositis) study was to evaluate the efficacy, safety and long-term tolerability of IVIg (Octagam 10%) in patients with DM in a randomized, placebo …
- Abstract - Europe PMC
Europe PMC is an archive of life sciences journal literature.
POS1229 DO MYOSITIS AUTOANTIBODIES PREDICT RESPONSE TO …
Objectives: Autoantibody status at baseline and its relationship to treatment response to IVIg were investigated in a post-hoc analysis of the randomized, placebo-controlled ProDERM study. Methods: …
National Center for Biotechnology Information
Efficacy of Intravenous Immunoglobulin for Systemic Manifestations of ...
Introduction Muscle and skin involvement are well defined in dermatomyositis but other symptoms contribute significantly to the disease burden and their treatment is not well characterized. This post …
POS1229 DO MYOSITIS AUTOANTIBODIES PREDICT RESPONSE TO …
Conclusion Myositis-specific antibodies were commonly identified in patients with dermatomyositis in the ProDERM study. Further analyses will determine if specific MSA, such as anti-TIF-1 and others, play …
Safety and tolerability of intravenous immunoglobulin in patients with ...
Background: Dermatomyositis is an idiopathic inflammatory myopathy characterised by rashes and progressive muscle weakness. The recent ProDERM (Progress in DERMatomyositis) study is the …
Dermatomyositis and Polymyositis Studies - The Myositis Association
See a list of published research relating to dermatomyositis and polymyositis. Click each study title to read the full study.